Presenilin 1 hemizygosity has no overt deleterious phenotypic outcomes in sheep: Potential implications for therapeutic targets in Alzheimer's disease.

Saved in:
Bibliographic Details
Title: Presenilin 1 hemizygosity has no overt deleterious phenotypic outcomes in sheep: Potential implications for therapeutic targets in Alzheimer's disease.
Authors: Mckean NE; Applied Translational Genetics Group, School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand. Electronic address: natasha.mckean@auckland.ac.nz., Liu J; Stem Cell and Genetic Engineering Group, Monash Institute of Medical Engineering, Faculty of Engineering, Monash University, Victoria 3800, Australia; TIGRR Lab, The School of BioSciences, University of Melbourne, Victoria 3010, Australia. Electronic address: jun.liu9@unimelb.edu.au., Rudiger SR; Molecular Biology and Reproductive Technology Laboratories, Livestock and Farming Systems Division, South Australian Research and Development Institute, Roseworthy, South Australia 5371, Australia. Electronic address: Skye.Rudiger@sa.gov.au., Kelly JM; Molecular Biology and Reproductive Technology Laboratories, Livestock and Farming Systems Division, South Australian Research and Development Institute, Roseworthy, South Australia 5371, Australia. Electronic address: jen.kelly@sa.gov.au., McLaughlan C; Molecular Biology and Reproductive Technology Laboratories, Livestock and Farming Systems Division, South Australian Research and Development Institute, Roseworthy, South Australia 5371, Australia. Electronic address: Clive.McLaughlan@sa.gov.au., Verma PJ; Molecular Biology and Reproductive Technology Laboratories, Livestock and Farming Systems Division, South Australian Research and Development Institute, Roseworthy, South Australia 5371, Australia. Electronic address: Paul.Verma@sa.gov.au., Hardy J; Department of Neurodegenerative Disease, UCL Dementia Research Institute, University College London, London WC1E 6BT, UK; UK Dementia Research Institute at UCL John Hardy, London WC1E 6BT, UK. Electronic address: j.hardy@ucl.ac.uk., Gusella JF; Center for Genomic Medicine, Massachusetts General Hospital and Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02114, USA. Electronic address: jGUSELLA@MGH.HARVARD.EDU., Zetterberg H; Department of Neurodegenerative Disease, UCL Dementia Research Institute, University College London, London WC1E 6BT, UK; UK Dementia Research Institute at UCL John Hardy, London WC1E 6BT, UK; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal S-431 80, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal S-431 80, Sweden; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA. Electronic address: h.zetterberg@ucl.ac.uk., Reid SJ; Applied Translational Genetics Group, School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand., Handley RH; Applied Translational Genetics Group, School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand. Electronic address: r.handley@auckland.ac.nz., Lehnert K; Applied Translational Genetics Group, School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand. Electronic address: klaus.lehnert@auckland.ac.nz., Sutherland GT; Neuroscience, School of Medical Sciences and Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney NSW 2050, Australia. Electronic address: g.sutherland@sydney.edu.au., Heslegrave A; Department of Neurodegenerative Disease, UCL Dementia Research Institute, University College London, London WC1E 6BT, UK; UK Dementia Research Institute at UCL John Hardy, London WC1E 6BT, UK. Electronic address: a.heslegrave@ucl.ac.uk., Veleva E; Department of Neurodegenerative Disease, UCL Dementia Research Institute, University College London, London WC1E 6BT, UK; UK Dementia Research Institute at UCL John Hardy, London WC1E 6BT, UK. Electronic address: e.veleva@ucl.ac.uk., Laban R; Department of Neurodegenerative Disease, UCL Dementia Research Institute, University College London, London WC1E 6BT, UK., Pearson JF; Biostatistics and Computational Biology Unit, Department of Medicine, University of Otago, Christchurch 8011, New Zealand. Electronic address: john.pearson@otago.ac.nz., Bawden SC; Molecular Biology and Reproductive Technology Laboratories, Livestock and Farming Systems Division, South Australian Research and Development Institute, Roseworthy, South Australia 5371, Australia. Electronic address: simon.bawden@sa.gov.au., Snell RG; Applied Translational Genetics Group, School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand. Electronic address: r.snell@auckland.ac.nz.
Source: Neurobiology of aging [Neurobiol Aging] 2025 Aug; Vol. 152, pp. 25-33. Date of Electronic Publication: 2025 Apr 25.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 8100437 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-1497 (Electronic) Linking ISSN: 01974580 NLM ISO Abbreviation: Neurobiol Aging Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-1497
DOI:10.1016/j.neurobiolaging.2025.04.006